CDIO Cardio Diagnostics Holdings, Inc.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1870144 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-3.8%
TTM net income YoY1.0%
TTM EPS YoY21.0%
Revenue 3-yr CAGR6.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-42,649.8%
Net margin-42,721.9%
FCF margin-38,090.8%
EBITDA margin-42,499.9%
Returns
ROE-93.5%
ROA-87.2%
ROIC (approx.)-136.2%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets6.0%
Debt / equity0.00x
Current ratio17.44x
Interest coverage-564.93x
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-9.5%
Payout ratio—
Capex / revenue11.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $14,825 | $34,890 |
| R&D expense | $641,212 | $227,966 |
| SG&A expense | $5.03M | $6.92M |
| Operating income | -$6.48M | -$8.37M |
| Interest expense | $14,801 | $18,640 |
| Pretax income | -$6.50M | -$8.38M |
| Net income | -$6.50M | -$8.38M |
| EBITDA | -$6.42M | -$8.35M |
| EPS (basic) | -3.71 | -9.35 |
| EPS (diluted) | -3.71 | -9.35 |
| Weighted avg. shares (diluted) | 1.75M | 896,424 |
| Balance sheet | ||
| Cash & equivalents | $0 | $7.83M |
| Receivables | $8,126 | $18,612 |
| Current assets | $5.92M | $8.79M |
| PP&E, net | $700,115 | $672,861 |
| Intangibles | — | $5,333 |
| Total assets | $7.77M | $10.62M |
| Current liabilities | $604,839 | $631,695 |
| Total liabilities | $793,061 | $1.06M |
| Shareholders' equity | $6.97M | $9.56M |
| Shares outstanding | 1.83M | 1.53M |
| Cash flow statement | ||
| Operating cash flow | -$5.73M | -$4.99M |
| Capital expenditure | $187,317 | $214,765 |
| Free cash flow | -$5.91M | -$5.21M |
| Investing cash flow | -$419,310 | -$404,190 |
| Financing cash flow | $3.43M | $11.94M |
| Depreciation & amortization | $65,233 | $19,738 |
| Stock-based compensation | $110,235 | $2.59M |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.